key: cord-0827759-xcgb9tuo
authors: Hassoun, Hayder K.; Radeef, Mohammed R.; Aljid, Zahra; Allebban, Zuhair
title: Fatal Case of COVID-19 Pneumonia Associated with Acute Myelopathy
date: 2021-06-17
journal: Case Rep Neurol
DOI: 10.1159/000513977
sha: 29de9a74989a9f0bb4503ce4fc65622f0f4de5a4
doc_id: 827759
cord_uid: xcgb9tuo

In December 2019, a novel coronavirus outbreak with multiple system involvement started initially in Wuhan City, Hubei Province of China. Coronavirus disease 2019 (COVID-19) infection is a systemic disorder typically presenting with fever, fatigue, and upper and lower respiratory symptoms, although neurological manifestations are increasingly reported, but pathological mechanisms have yet to be established. The symptoms of infection with COVID-19 are dependent on the patient's age and underlying medical illness, and on the condition of the immune system. Neurotropic and neuroinvasive capabilities of coronaviruses have been described in humans. We herein report a patient infected with COVID-19 who developed pneumonia associated with acute progressive myelopathy. Neurological examination revealed progressive flaccid areflexic paralysis of lower limbs over 3 days with retention of urine and sensory level at 10th spinal thoracic segment (T10). The patient had a positive nasopharyngeal swab for COVID-19 at the onset of the neurological symptoms. This case of acute progressive myelopathy adds further evidence of the complications of severe COVID-19 infection, and we are dealing with a virus of unpredictable behavior. Since this virus neurotropism is not clear yet, further investigations should be conducted on the mechanism of possible neurological infection in patients with COVID-19.

In December 2019, the first case of pneumonia with unknown etiology was reported in Wuhan city, China [1] . The identified pathogen was a novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which would be later known as COVID-19. COVID-19 spread to Europe, North America, and Asia within a short time [2, 3] and caused significant public fear and stressed the healthcare systems all over the world. Although most have mild symptoms, such as fever, headache, cough, dyspnea, myalgia, and anosmia, some developed acute respiratory distress syndrome about a week into the illness, which can result in death [2, 4] In a recent COVID 19 study, neurological symptoms and manifestations were reported in 37% (50% in severe infection) of 214 COVID-19 patients reported from Wuhan, including nonspecific symptoms of headache and dizziness (20% of cases), altered mentation (15% of severe infection), severe muscle ache and myalgia (20% of cases), and loss of taste and smell sense, which may give initial clue to COVID-19 infection [2] . Other neurological complications were reported in association, including viral meningitis, encephalitis, postinfectious acute disseminated encephalomyelitis, postinfectious brainstem encephalitis, acute necrotizing encephalitis, Guillain-Barré syndrome (GBS), myositis, and cerebrovascular accident [4] [5] [6] [7] . Coronaviruses in general are considered respiratory viruses, but recent reports have also shown that they are able to infect the central nervous system (CNS) and cause neurological disorders [6] . It has been reported that coronavirus infects the nasal mucous membrane and enters the CNS through the olfactory bulb, blood circulation, ACE2 in brainstem, immune injury, and neuronal pathways, resulting in neurological disorders and also causing inflammation and demyelination. In this report, we present a fatal COVID-19 infection associated with acute progressive myelopathy which is rarely reported in COVID-19 infections.

The patient was a 77-year-old Iraqi male with a history of hypertension, diabetes, and ischemic heart disease who was on captopril 25 mg tablet twice daily for hypertension, metformin 500 mg tablet twice daily for diabetes, and aspirin 100 mg tablet once daily with atorvastatin 20 mg tablet. He was admitted to the emergency department at Kufa University teaching hospital in the city of Al-Najaf Al-Ashraf in Iraq. He presented with progressive weakness in his lower limbs for 3 days, retention of urine, loss of all sensations in the lower limbs up to umbilicus level. His presentation was preceded by 4 days of febrile illness but no shortness of breath or cough. General examination was good with full consciousness (wakeful and alert) and normal vital signs. Apart from low-grade fever (38°C), there was no dyspnea or tachypnea; chest auscultation showed fine crackles and normal S1 and S2 heart sounds. The abdomen was soft with palpable distended bladder. Neurological examination revealed normal higher cerebral function including speech and intact cranial nerves. Upper limb examination showed normal strength (power grade 5/5); reflexes were +2 with normal sensory examination. Lower limb examination revealed flaccid paralysis (power grade 0/5) and hypotonia, and reflexes were grade 0 with initially bilateral mute planter reflex, then after 2 days it became extensor. Sensory level was at T10 (umbilicus level), and below it, all modality of sensations (sensations, pain, temperature, touch, vibration, and joint position) had been lost with retention of urine. Initial laboratory results revealed elevated WBC count with lymphopenia and elevated renal indices. Chest CT showed typical feature of COVID-19 ( Fig. 1, 2) with typical finding of multiple peripheral ground-glass pulmonary opacities, more so in upper lobes and associated with fine reticulation with interlobar septal thickening. Cervical dorsal area MRI (Fig. 3) and lumbosacral spine (Fig. 4, 5) were done in the emergency unit without the use of contrast (because of renal impairment) revealing normal degenerative change without any obvious lesion mentioned. Other viral and bacterial causes of infectious myelitis were excluded by PCR screening and serology tests. PCR test was used for cytomegalovirus, Epstein-Barr virus, herpes simplex virus type 1 (HSV-1), HSV-2 and serology test for hepatitis C virus, Mycoplasma pneumoniae, and Brucella; all tests were negative. The interferon gamma release assays test using Quanti FERON ® -TB Gold In-Tube test was negative for Mycobacterium tuberculosis. The patient was immediately isolated and kept on 1 g methylprednisolone i.v. solution (Solu-Medrol-Pfizer) pulse therapy with control of hyperglycemia by insulin therapy, ceftriaxone (Mesporin-Mepha) 1 g i.v. infusion twice daily, and azithromycin capsule (Azi-Once/Jamjoom Pharma) 250 mg two capsules once daily. He was referred to the local hospital designated to care for COVID-19 on the second day after a positive real-time reverse transcription polymerase chain reaction RT-PCR test result.

The real-time reverse transcription polymerase chain reaction test for SARS-CoV-2 was completed using a nasopharyngeal swab transported in an M4 viral tube to the hospital central laboratory for analysis. In the following 2 days, the patient's condition progressively deteriorated with shortening of breath, and he was admitted to the intensive care unit and kept on mechanical ventilation where he died 4 days later due to multiorgan failure and septicemia.

The neurological components are obviously not the major focus of COVID-19 infection. It is still early to conclude that the virus is neurotropic, and the neurological complications in our case are possibly an indirect effect of the infection. Previous studies reported that COVID-19 patients showed neurological signs such as headache, nausea, and vomiting [8] , while one study reported COVID-19 patients with severe symptoms did show acute cerebrovascular disease and impaired consciousness and also suggested a possible neuroinvasion [2] .

The reported COVID-19 cases with neurological manifestations tend to occur more frequently in severe infections and in older people with comorbidities, such as diabetes mellitus (DM) and hypertension [5, 9] . It has been reported that SARS-CoV and MERS-CoV coronaviruses were detected in the CSF of a patient with encephalitis and acute respiratory distress syndrome [10] , and these viruses along with COVID-19 have ACE-2 receptors on the respiratory epithelial cells, glial cells, neurons, and vascular endothelium [5, 6] , which may indicate that COVID-19 possibly target and damage the nerve tissues. Myelopathy is rarely reported in association with COVID-19 infection. Three COVID-19 cases of myelitis were published recently, the first case from Wuhan, China, with myelitis associated with COVID-19 [11] , the second case from Boston, USA, where the patient presented with respiratory symptoms and then developed acute myelitis 7 days later [12] , and the third case was a 32-year-old COVID-19positive male who presented with a 2-day history of flu-like symptoms followed by a sudden onset paraplegia and urinary retention [13] .

Our initial diagnosis was GBS, but the presence of sensory level, Babinski signs, and retention of urine make neuropathy (GBS) unlikely, and myelopathy was our provisional diagnosis and most probably inflammatory, as vascular myelopathy is unlikely to present with progression over days with loss of all modality sensation. Lumbosacral and dorsal spine MRI were unremarkable, which has been reported in transverse myelitis with normal MRI [14] . We recognize that the main limitation was that we could not arrange for CSF examination because of referral of the patient to a hospital that cares for COVID-19 patients, during an extreme circumstance in our hospital at the peak of this pandemic, in addition to rapid deterioration in the patient clinical status. The patient died shortly after the onset of infection with respiratory failure.

COVID-19 may play a role either through direct virus effect that may be confirmed by the isolation of the virus from the cerebrospinal fluid and autopsies of the victims, or indirectly via an abnormal immune or inflammatory reaction due to the cytokine storm [15] . The application of modern technologies, such as genetic sequencing, is warranted as this may determine the direct link between the virus and neuronal manifestations.

Written informed consent from the patient's next of kin to publish the findings of this case along with the accompanying images was obtained, without revealing the patient's identity. An approval letter from the Institutional Review Board at Kufa University was obtained. 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

COVID-19) Pandemic. Geneva: World Health Organization

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Neurological manifestations of COVID-19: available evidences and a new paradigm

Coronaviruses and the central nervous system

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

SARS-CoV-2 and Nervous System-Neurological Manifestations in Patients With COVID-19: A Systematic Review

Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome

Acute myelitis after SARS-CoV-2 infection: a case report

A case report of acute transverse myelitis following novel coronavirus infection. Clin Pract Cases Emerg Med

Acute transverse myelitis after COVID-19 pneumonia

Myelopathy but normal MRI: where next? Pract Neurol

HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

The authors have no conflicts of interest to declare.

No funding was obtained for this study.